应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01477 欧康维视生物-B
未开盘 04-30 16:08:06
7.180
+0.370
+5.43%
最高
7.260
最低
6.840
成交量
251.83万
今开
6.840
昨收
6.810
日振幅
6.17%
总市值
49.95亿
流通市值
49.95亿
总股本
6.96亿
成交额
1,783万
换手率
0.36%
流通股本
6.96亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
再生元制药上涨1.21%,报901.44美元/股
金融界 · 00:19
再生元制药上涨1.21%,报901.44美元/股
欧康维视生物-B(01477)上涨5.43%,报7.18元/股
金融界 · 04-30 14:05
欧康维视生物-B(01477)上涨5.43%,报7.18元/股
欧康维视生物-B盘中异动 急速拉升5.43%报7.180港元
自选股智能写手 · 04-30 14:05
欧康维视生物-B盘中异动 急速拉升5.43%报7.180港元
欧康维视生物-B(01477)股价上升5.433%,现价港币$7.18
阿斯达克财经 · 04-30 14:05
欧康维视生物-B(01477)股价上升5.433%,现价港币$7.18
A股三大指数集体下挫 创业板指跌逾1% 化学制药、家电板块涨幅居前
东方财富网 · 04-30 11:30
A股三大指数集体下挫 创业板指跌逾1% 化学制药、家电板块涨幅居前
受药物安全问题报道冲击,Morphosys(MOR.US)称诺华制药(NVS.US)收购仍将按计划进行
智通财经 · 04-29 20:21
受药物安全问题报道冲击,Morphosys(MOR.US)称诺华制药(NVS.US)收购仍将按计划进行
欧康维视生物-B(01477)上涨5.1%,报6.8元/股
金融界 · 04-29 09:58
欧康维视生物-B(01477)上涨5.1%,报6.8元/股
再传捷报!亚信科技&用友,助力某龙头制药企业搭建数智运营平台
市场资讯 · 04-28
再传捷报!亚信科技&用友,助力某龙头制药企业搭建数智运营平台
10亿美元种子轮融资!诺奖得主加盟、斯坦福前校长掌舵
创业邦 · 04-28
10亿美元种子轮融资!诺奖得主加盟、斯坦福前校长掌舵
歌礼制药-B:2023年度报告显著提升在慢性乙肝治疗方面的业务发展,成功入组49例基线HBsAg≤100 IU/mL患者进行ASC22治疗
金融界港股 · 04-26
歌礼制药-B:2023年度报告显著提升在慢性乙肝治疗方面的业务发展,成功入组49例基线HBsAg≤100 IU/mL患者进行ASC22治疗
欧康维视生物-B(01477)上涨5.17%,报6.31元/股
金融界 · 04-26
欧康维视生物-B(01477)上涨5.17%,报6.31元/股
欧康维视生物-B盘中异动 股价大涨5.17%报6.310港元
自选股智能写手 · 04-26
欧康维视生物-B盘中异动 股价大涨5.17%报6.310港元
歌礼制药-B(01672)下跌5.15%,报1.29元/股
金融界 · 04-26
歌礼制药-B(01672)下跌5.15%,报1.29元/股
歌礼制药-B盘中异动 早盘股价大跌5.22%
自选股智能写手 · 04-26
歌礼制药-B盘中异动 早盘股价大跌5.22%
全国三成AI药企汇聚上海张江,首款进入临床AI药物诞生
蓝鲸财经 · 04-26
全国三成AI药企汇聚上海张江,首款进入临床AI药物诞生
再生元制药下跌3.13%,报878.2美元/股
金融界 · 04-25
再生元制药下跌3.13%,报878.2美元/股
沈阳红旗制药:自主研发环丝氨酸胶囊获国家药品监督管理局上市批准
和讯网 · 04-24
沈阳红旗制药:自主研发环丝氨酸胶囊获国家药品监督管理局上市批准
小方制药IPO前大股东分走5.2亿,实控人方之光一家三口加拿大籍
地产k线 · 04-23
小方制药IPO前大股东分走5.2亿,实控人方之光一家三口加拿大籍
石药创新制药总经理、董事辞任
医药魔方 · 04-23
石药创新制药总经理、董事辞任
加载更多
公司概况
公司名称:
欧康维视生物-B
所属市场:
SEHK
上市日期:
--
主营业务:
欧康维视生物是一家主要从事眼科疗法发现、开发及商业化业务的中国控股公司。其主要产品包括OT-401(YUTIQ)、OT-1001(ZERVIATE)、OT-502(DEXYCU)、OT-301(NCX 470)、OT-101和OT-202等。该公司在中国境内开展业务。
发行价格:
--
{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":7.18,"timestamp":1714464486028,"preClose":6.81,"halted":0,"volume":2518275,"delay":0,"floatShares":695614850,"shares":695614850,"eps":-0.6326297,"marketStatus":"未开盘","marketStatusCode":0,"change":0.37,"latestTime":"04-30 16:08:06","open":6.84,"high":7.26,"low":6.84,"amount":17833218,"amplitude":0.061674,"askPrice":7.18,"askSize":2000,"bidPrice":7,"bidSize":4500,"shortable":3,"etf":0,"ttmEps":-0.6326296749595138,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714613400000},"adr":0,"listingDate":1594310400000,"adjPreClose":6.81,"openAndCloseTimeList":[[1714440600000,1714449600000],[1714453200000,1714464000000]],"volumeRatio":2.0396915622674716,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477","defaultTab":"news","newsList":[{"id":"2432683160","title":"再生元制药上涨1.21%,报901.44美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2432683160","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2432683160?lang=zh_cn&edition=full","pubTime":"2024-05-02 00:19","pubTimestamp":1714580349,"startTime":"0","endTime":"0","summary":"5月2日,再生元制药(REGN)盘中上涨1.21%,截至00:19,报901.44美元/股,成交1.24亿美元。财务数据显示,截至2023年12月31日,再生元制药收入总额131.17亿美元,同比增长7.76%;归母净利润39.54亿美元,同比减少8.87%。大事提醒:5月2日,再生元制药将于(美东)盘前披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/05/02001940507063.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431351081","title":"欧康维视生物-B(01477)上涨5.43%,报7.18元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431351081","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431351081?lang=zh_cn&edition=full","pubTime":"2024-04-30 14:05","pubTimestamp":1714457128,"startTime":"0","endTime":"0","summary":"4月30日,欧康维视生物-B(01477)盘中上涨5.43%,截至14:05,报7.18元/股,成交955.34万元。欧康维视生物是一家专注于眼科医药领域的公司,主要业务包括识别、开发和商业化眼科疗法。公司自成立以来,一直致力于构建整合研发、制造到商业化的眼科药物开发全周期专业能力,以满足中国眼科医疗的巨大需求缺口。截至2023年年报,欧康维视生物-B营业总收入2.46亿元、净利润-3.8亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/30140540489607.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431354694","title":"欧康维视生物-B盘中异动 急速拉升5.43%报7.180港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431354694","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431354694?lang=zh_cn&edition=full","pubTime":"2024-04-30 14:05","pubTimestamp":1714457124,"startTime":"0","endTime":"0","summary":"2024年04月30日下午盘14时05分,欧康维视生物-B股票出现异动,股价大幅拉升5.43%。截至发稿,该股报7.180港元/股,成交量136.028万股,换手率0.20%,振幅4.99%。资金方面,该股资金流入420.613万港元,流出474.717万港元。欧康维视生物-B股票所在的生物技术行业中,整体跌幅为0.16%。其相关个股中,北海康成-B、君实生物、欧康维视生物-B涨幅较大,振幅较大的相关个股有科笛-B、乐普生物-B、迈博药业-B,振幅分别为27.56%、15.86%、15.66%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043014052487e84fdb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043014052487e84fdb&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431226351","title":"欧康维视生物-B(01477)股价上升5.433%,现价港币$7.18","url":"https://stock-news.laohu8.com/highlight/detail?id=2431226351","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2431226351?lang=zh_cn&edition=full","pubTime":"2024-04-30 14:05","pubTimestamp":1714457100,"startTime":"0","endTime":"0","summary":"[上升股]欧康维视生物-B(01477) 股价在下午02:05比前收市价上升5.433%,现股价为港币$7.18。至目前为止,今日最高价为$7.18,而最低价为$6.84。总成交量为136.028万股,总成交金额为港币$955.342万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2404301033/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2431364483","title":"A股三大指数集体下挫 创业板指跌逾1% 化学制药、家电板块涨幅居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2431364483","media":"东方财富网","top":-1,"share":"https://www.laohu8.com/m/news/2431364483?lang=zh_cn&edition=full","pubTime":"2024-04-30 11:30","pubTimestamp":1714447800,"startTime":"0","endTime":"0","summary":" A股三大指数集体下挫,创业板指跌逾1%。盘面上,化学制药、家电、维生素、中药、钛白粉、宠物经济、猪肉概念等板块位于涨幅榜前列。 截至4月29日23时30分,A股共有5256家上市公司对外披露2023年年报,3031家上市公司实现营业收入同比增长,2683家上市公司实现归属于上市公司股东的净利润同比增长。工商银行、建设银行2023年拟累计分红总额超过1000亿元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-04-30/doc-inatqssz2323767.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-04-30/doc-inatqssz2323767.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431594928","title":"受药物安全问题报道冲击,Morphosys(MOR.US)称诺华制药(NVS.US)收购仍将按计划进行","url":"https://stock-news.laohu8.com/highlight/detail?id=2431594928","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431594928?lang=zh_cn&edition=full","pubTime":"2024-04-29 20:21","pubTimestamp":1714393287,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,周一,德国生物技术公司Morphosys股价下滑,受到一则关于其药物或具有安全风险的新闻报道影响,但Morphosys表示,诺华制药对其收购仍有望在今年上半年完成。Pelabresib被视为Morphosys公司最有前途的药物之一,也是诺华制药对该公司感兴趣的原因之一。Morphosys发言人补充道:“诺华的收购计划正在稳步推进。”诺华制药于今年2月达成协议,将以27亿欧元的价格收购Morphosys公司。截至发稿,Morphosys美股盘前下跌2.38%,诺华制药美股盘前上涨了0.63%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1114925.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431042211","title":"欧康维视生物-B(01477)上涨5.1%,报6.8元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431042211","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431042211?lang=zh_cn&edition=full","pubTime":"2024-04-29 09:58","pubTimestamp":1714355913,"startTime":"0","endTime":"0","summary":"4月29日,欧康维视生物-B(01477)盘中上涨5.1%,截至09:58,报6.8元/股,成交336.21万元。欧康维视生物是一家专注于眼科医药领域的公司,主要业务包括识别、开发和商业化眼科疗法。公司自成立以来,一直致力于构建整合研发、制造到商业化的眼科药物开发全周期专业能力,以满足中国眼科医疗的巨大需求缺口。截至2023年年报,欧康维视生物-B营业总收入2.46亿元、净利润-3.8亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/29095840459061.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430081500","title":"再传捷报!亚信科技&用友,助力某龙头制药企业搭建数智运营平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2430081500","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2430081500?lang=zh_cn&edition=full","pubTime":"2024-04-28 14:53","pubTimestamp":1714287180,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 亚信科技AntDB数据库,医疗行业再下一城! 近日,亚信科技(中国)有限公司‘简称“亚信科技”’与用友网络科技股份有限公司‘简称“用友”’携手推出的“U8C+AntDB”联合产品正式落地东北某龙头制药企业,助其完成“业务+数据”双底座建设,向“数智制药”全面迈进。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/roll/2024-04-28/doc-inatkkuz3824586.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2024-04-28/doc-inatkkuz3824586.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430700953","title":"10亿美元种子轮融资!诺奖得主加盟、斯坦福前校长掌舵","url":"https://stock-news.laohu8.com/highlight/detail?id=2430700953","media":"创业邦","top":-1,"share":"https://www.laohu8.com/m/news/2430700953?lang=zh_cn&edition=full","pubTime":"2024-04-28 11:01","pubTimestamp":1714273260,"startTime":"0","endTime":"0","summary":"10亿美元中,有超过2亿美元来自ARCH Venture Partners。比如曾经领导基因泰克大分子药物发现的Arvind Rajpal博士、任职于基因泰克超过13年,目前是Xaira的副总裁的Don Kirkpatrick,还有2022年诺贝尔化学奖得主、斯坦福大学的化学教授Carolyn Bertozzi等等。这一次,Xaira喜获10亿美元融资受到万众瞩目,AI制药领域也因此再次获得了不少关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MjM5OTAzMjc4MA==&mid=2650710683&idx=1&sn=519692ef69536589e30c32d76c4161cf&chksm=bfbd4b8ed4de65a818d6137c1f5574d1ac7f18cbcc315307f663f5e1d3fe199a19021a78d4df&scene=0#rd","is_publish_highlight":false,"gpt_icon":0},{"id":"2430724772","title":"歌礼制药-B:2023年度报告显著提升在慢性乙肝治疗方面的业务发展,成功入组49例基线HBsAg≤100 IU/mL患者进行ASC22治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2430724772","media":"金融界港股","top":-1,"share":"https://www.laohu8.com/m/news/2430724772?lang=zh_cn&edition=full","pubTime":"2024-04-26 16:57","pubTimestamp":1714121839,"startTime":"0","endTime":"0","summary":"金融界4月26日消息,歌礼制药-B在其最新的2023年度报告中显著提升了在慢性乙肝治疗方面的业务发展。其在ASC22(恩沃利单抗)用于慢性乙肝功能性治愈的IIb期扩展队列研究,已经成功完成49例基线HBsAg≤100 IU/mL患者入组。该研究的期中结果已在2023年十一月美国肝病研究协会年会上展示。此外,治疗结束后再进行24周随访,期中分析已完成约50%入组患者的24周ASC22或安慰剂治疗。ASC22单药结合NAs背景治疗显示出了统计学意义的HBsAg显著下降,且24周治疗后,21.1%(4/19)的患者实现HBsAg清除。\n\n\r\n 责任编辑:钟离","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/26165740432114.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430219412","title":"欧康维视生物-B(01477)上涨5.17%,报6.31元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430219412","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430219412?lang=zh_cn&edition=full","pubTime":"2024-04-26 13:43","pubTimestamp":1714110229,"startTime":"0","endTime":"0","summary":"4月26日,欧康维视生物-B(01477)盘中上涨5.17%,截至13:43,报6.31元/股,成交579.13万元。欧康维视生物是一家专注于眼科医药领域的公司,主要业务包括识别、开发和商业化眼科疗法。公司自成立以来,一直致力于构建整合研发、制造到商业化的眼科药物开发全周期专业能力,以满足中国眼科医疗的巨大需求缺口。截至2023年年报,欧康维视生物-B营业总收入2.46亿元、净利润-3.8亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/26134340425833.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430211147","title":"欧康维视生物-B盘中异动 股价大涨5.17%报6.310港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430211147","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430211147?lang=zh_cn&edition=full","pubTime":"2024-04-26 13:43","pubTimestamp":1714110224,"startTime":"0","endTime":"0","summary":"2024年04月26日下午盘13时43分,欧康维视生物-B股票出现波动,股价快速上涨5.17%。截至发稿,该股报6.310港元/股,成交量93.4万股,换手率0.13%,振幅5.17%。资金方面,该股资金流入293.971万港元,流出200.237万港元。欧康维视生物-B股票所在的生物技术行业中,整体涨幅为1.25%。欧康维视生物-B公司简介:欧康维视生物是一家主要从事眼科疗法发现、开发及商业化业务的中国控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261343447923bd1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261343447923bd1c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430621942","title":"歌礼制药-B(01672)下跌5.15%,报1.29元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430621942","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430621942?lang=zh_cn&edition=full","pubTime":"2024-04-26 13:37","pubTimestamp":1714109838,"startTime":"0","endTime":"0","summary":"4月26日,歌礼制药-B(01672)盘中下跌5.15%,截至13:37,报1.29元/股,成交118.5万元。歌礼制药是一家致力于为抗病毒、癌症和脂肪肝等领域提供创新治疗方案的生物科技公司,覆盖从新药研发到生产和商业化的完整价值链。公司以高度一体化的抗病毒平台为基础,专注于为慢性丙肝、慢性乙肝和艾滋病患者提供创新药物,使其得到可负担的医疗解决方案。截至2023年年报,歌礼制药-B营业总收入5659.6万元、净利润-1.45亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/26133740425719.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430292201","title":"歌礼制药-B盘中异动 早盘股价大跌5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430292201","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430292201?lang=zh_cn&edition=full","pubTime":"2024-04-26 11:17","pubTimestamp":1714101432,"startTime":"0","endTime":"0","summary":"2024年04月26日早盘11时17分,歌礼制药-B股票出现波动,股价急速跳水5.22%。截至发稿,该股报1.290港元/股,成交量31.5万股,换手率0.03%,振幅3.68%。歌礼制药-B股票所在的生物技术行业中,整体涨幅为0.95%。歌礼制药-B公司简介:歌礼制药股份有限公司是一家主要从事医药产品的研发、生产、行销及销售的中国投资控股公司。该公司主要专注于病毒性疾病、非酒精性脂肪性肝炎及肿瘤领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261117127923b3f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261117127923b3f8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430970291","title":"全国三成AI药企汇聚上海张江,首款进入临床AI药物诞生","url":"https://stock-news.laohu8.com/highlight/detail?id=2430970291","media":"蓝鲸财经","top":-1,"share":"https://www.laohu8.com/m/news/2430970291?lang=zh_cn&edition=full","pubTime":"2024-04-26 10:43","pubTimestamp":1714099414,"startTime":"0","endTime":"0","summary":"经药物“发现”阶段后的候选药物,药物化学家会致力于提高它们的活性和优化成药性,并完善安全性。如果实验成功,研究人员将开发一种临床前候选化合物进入临床前测试。虽然“AI+新药研发”正在被业内普遍看好且重点布局,但行业一直在等待一款AI研发的重磅药物诞生。据悉,目前该药物已经进入2期临床试验正在患者群体中做进一步的验证,有望成为全球范围内首批真正惠及患者的AI药物之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/231070","is_publish_highlight":false,"gpt_icon":0},{"id":"2430287529","title":"再生元制药下跌3.13%,报878.2美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430287529","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430287529?lang=zh_cn&edition=full","pubTime":"2024-04-25 22:43","pubTimestamp":1714056209,"startTime":"0","endTime":"0","summary":"4月25日,再生元制药(REGN)盘中下跌3.13%,截至22:43,报878.2美元/股,成交1.28亿美元。财务数据显示,截至2023年12月31日,再生元制药收入总额131.17亿美元,同比增长7.76%;归母净利润39.54亿美元,同比减少8.87%。大事提醒:5月2日,再生元制药将于(美东)盘前披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/25224340415232.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430478626","title":"沈阳红旗制药:自主研发环丝氨酸胶囊获国家药品监督管理局上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2430478626","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2430478626?lang=zh_cn&edition=full","pubTime":"2024-04-24 17:22","pubTimestamp":1713950565,"startTime":"0","endTime":"0","summary":"快讯正文【复星医药成功研发新药 获国家药品监督管理局批准上市】复星医药公告,其控股子公司沈阳红旗制药有限公司自主创新研发的环丝氨酸胶囊已经获得国家药品监督管理局的官方批准,用于治疗对一线抗结核药物不敏感的结核病患者。该胶囊适用于结核菌引起的活动性肺结核及肺外结核(包括肾结核)的治疗。环丝氨酸胶囊的上市注册申请属于自主研发,标志着复星医药在抗结核药物领域的技术实力。复星医药表示,环丝氨酸胶囊的上市将增强其在抗结核药物市场的竞争力,为公司业绩增长带来新的增长点。公司将致力于提升产品质量,优化生产工艺,不断满足市场需求,助力中国抗结核药物研发事业的发展。下载和讯APP查看快讯,体验更佳>>","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042417385487aa4213&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042417385487aa4213&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429590141","title":"小方制药IPO前大股东分走5.2亿,实控人方之光一家三口加拿大籍","url":"https://stock-news.laohu8.com/highlight/detail?id=2429590141","media":"地产k线","top":-1,"share":"https://www.laohu8.com/m/news/2429590141?lang=zh_cn&edition=full","pubTime":"2024-04-23 10:47","pubTimestamp":1713840440,"startTime":"0","endTime":"0","summary":"瑞财经 李兰 4月20日消息,据小方制药微信公众号,上海小方制药股份有限公司(以下简称“小方制药”)发布数篇“媒体报道”文章,文章内容涉及品牌建设、市场推广等方面。据瑞财经查阅,小方制药已取得中国证监会同意其首次公开发行股票注册的批复。但截至目前,小方制药仍未启动发行。招股书显示,小方制药的主营业务为外...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OaSVxu2vKj0jCi7V9uk6gqWqAHYslaZzxS6H9SbQjfqLQAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OaSVxu2vKj0jCi7V9uk6gqWqAHYslaZzxS6H9SbQjfqLQAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240423A02QVK00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240423A02QVK00","is_publish_highlight":false,"gpt_icon":0},{"id":"2429854201","title":"石药创新制药总经理、董事辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=2429854201","media":"医药魔方","top":-1,"share":"https://www.laohu8.com/m/news/2429854201?lang=zh_cn&edition=full","pubTime":"2024-04-23 07:42","pubTimestamp":1713829325,"startTime":"0","endTime":"0","summary":"4月22日,石药创新制药即新诺威发布公告,宣布董事会收到总经理韩峰先生及董事王怀玉先生的书面辞任报告。因工作调整需要,韩峰先生申请辞任公司总经理职务,将继续担任公司董事职务,并分管公司功能性原料相关业务。韩峰先生总经理职务的原定任期届满之日为2026年4月6日。同日,新诺威发布2024Q1业绩,公司实现营业总收入5.24亿元,同比下降27.08%。此外,新诺威2024Q1归属于上市公司股东的扣除非经常性损益的净利润为7817.20万元,同比下降56.44%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404230804368b47e01e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404230804368b47e01e&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.2047},{"period":"1month","weight":0.2422},{"period":"3month","weight":0.4303},{"period":"6month","weight":-0.0663},{"period":"1year","weight":-0.1859},{"period":"ytd","weight":0.0749}],"compareEarnings":[{"period":"1week","weight":0.0555},{"period":"1month","weight":0.0739},{"period":"3month","weight":0.1471},{"period":"6month","weight":0.0309},{"period":"1year","weight":-0.1071},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科疗法发现、开发及商业化业务的中国控股公司。其主要产品包括OT-401(YUTIQ)、OT-1001(ZERVIATE)、OT-502(DEXYCU)、OT-301(NCX 470)、OT-101和OT-202等。该公司在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.137321},{"month":2,"riseRate":0.25,"avgChangeRate":-0.072355},{"month":3,"riseRate":0.5,"avgChangeRate":0.043389},{"month":4,"riseRate":0.25,"avgChangeRate":0.004659},{"month":5,"riseRate":0.666667,"avgChangeRate":0.10927},{"month":6,"riseRate":0.666667,"avgChangeRate":0.085171},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.038817},{"month":8,"riseRate":0.5,"avgChangeRate":-0.01818},{"month":9,"riseRate":0,"avgChangeRate":-0.13975},{"month":10,"riseRate":0.25,"avgChangeRate":-0.152265},{"month":11,"riseRate":0.5,"avgChangeRate":0.029996},{"month":12,"riseRate":0.75,"avgChangeRate":0.144341}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}